Chardan Healthcare Acquisition 2 Corp. (CHAQ): Price and Financial Metrics

Chardan Healthcare Acquisition 2 Corp. (CHAQ): $10.00

0.05 (+0.50%)

POWR Rating

Component Grades













CHAQ Stock Price Chart Interactive Chart >

Price chart for CHAQ

CHAQ Price/Volume Stats

Current price $10.00 52-week high $11.37
Prev. close $9.95 52-week low $9.57
Day low $10.00 Volume 10,200
Day high $10.01 Avg. volume 53,299
50-day MA $10.08 Dividend yield N/A
200-day MA $10.08 Market Cap 107.78M

Chardan Healthcare Acquisition 2 Corp. (CHAQ) Company Bio

Chardan Healthcare Acquisition 2 Corp. intends to acquire assets and businesses through a merger, share exchange, stock purchase, recapitalization, reorganization, or other similar business combination. The company was founded in 2018 and is based in New York, New York.

CHAQ Latest News Stream

Event/Time News Detail
Loading, please wait...

CHAQ Latest Social Stream

Loading social stream, please wait...

View Full CHAQ Social Stream

Latest CHAQ News From Around the Web

Below are the latest news stories about Chardan Healthcare Acquisition 2 Corp that investors may wish to consider to help them evaluate CHAQ as an investment opportunity.

Lifshitz Law Firm, P.C. Announces Investigation of ARPO, CNBKA, CHAQ, DSSI, INSW, FORE, FTIV, ONB, FMBI, and GRA

Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO)

Yahoo | June 11, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Chardan Healthcare Acquisition 2 Corp. Merger

WILMINGTON, Del., June 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Chardan Healthcare Acquisition 2 Corp. (“Chardan Healthcare”) (NYSE: CHAQ) regarding possible breaches of fiduciary duties and other violations of law related to Chardan Healthcare’s agreement to merge with Renovacor, Inc. To learn more about this investigation and your rights, visit: You may also contact Seth D. Rigrodsk

Yahoo | June 7, 2021

Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer

Former chief medical officer of MyoKardia to lead clinical development at RenovacorPHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor. Dr. Semigran brings cons

Yahoo | June 2, 2021

Here's What Chardan Healthcare Acquisition 2 Corp.'s (NYSEMKT:CHAQ) Shareholder Ownership Structure Looks Like

The big shareholder groups in Chardan Healthcare Acquisition 2 Corp. ( NYSEMKT:CHAQ ) have power over the company...

Yahoo | February 28, 2021

Read More 'CHAQ' Stories Here

CHAQ Price Returns

1-mo N/A
3-mo -0.99%
6-mo -2.86%
1-year N/A
3-year N/A
5-year N/A
YTD -1.96%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7988 seconds.